Spinogenix

CompanyUnited States

Spinogenix develops one asset, in phase 2 (Tazbentetol in ALS). Mostly small molecule; based in the United States.

1
Asset
Furthest stage
Phase 2
5
Trials
0
Signals

Pipeline

1
  • Tazbentetol

    Oral transient activator of glutamatergic synapses promoting synaptic regeneration

    Phase 2, Small molecule, ALS, Alzheimer's disease

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Trials5
  • Signals2
  • Similar companies6

Intelligence